58例炎性肌纤维母细胞瘤临床特点与疗效分析

doi:10.3760/cma.j.issn.1004-4221.2017.06.008

Abstract
Figure/Table
References()
Related Citation (15)
Read Tracking
Download Tracking

Download: PDF (766 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS) Supporting Info

Abstract Objective To evaluate the risk of locoregional recurrence (LRR) and the influencing factors for long-term survival in patients with inflammatory myofibroblastic tumor (IMT). Methods A retrospective analysis was performed for 58 IMT patients who completed initial therapy or initial adjuvant therapy in our hospital from January 2002 to January 2017 to evaluate their failure patterns and survival. The LRR and survival rates were compared between groups. The Kaplan-Meier method was used to calculate survival rates,and the log-rank test was used for survival difference analysis and univariate prognostic analysis. Results The median follow-up time was 34 months. Among the 58 patients,50 underwent surgery alone,and 8 underwent surgery and adjuvant therapy. Seventeen patients experienced treatment failure,16 patients developed LRR,3 patients developed distant metastasis,including 2 patients with local failure,and 5 patients died of tumor recurrence or metastasis. The 5-year LRRFS was 75%,and the 5-year OS rate was 90%.The univariate analysis showed that resection margin and local staging were influencing factors for LRRFS (P=0.018,0). Conclusions Radical resection combined with adjuvant therapy is the key to improving the treatment outcome of IMT.

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Zhang Jianghu
	Gao Li
	Yi Junlin
	Yang Lin
	Xu Guozhen
	Luo Jingwei
	Xiao Jianping
	Wang Kai
	Qu Yuan
	Zhang Shiping
	Huang Xiaodong

Key words： Inflammatory myofibroblastic neoplasms/surgery Inflammatory myofibroblastic neoplasms/postoperative radiotherapy Treatment outcome

Received: 10 April 2017

Corresponding Authors: :Huang Xiaodong,Email:whxd010@163.com

Cite this article:

Zhang Jianghu,Gao Li,Yi Junlin et al. Clinical features and treatment outcome of inflammatory myofibroblastic tumor:a retrospective study of 58 patients[J]. Chinese Journal of Radiation Oncology, 2017, 26(6): 646-649.

URL:

http://journal12.magtechjournal.com/Jweb_fszlx/EN/10.3760/cma.j.issn.1004-4221.2017.06.008 OR http://journal12.magtechjournal.com/Jweb_fszlx/EN/Y2017/V26/I6/646

[1] Brunn H.Two interesting benign lung tumor of contradictory histopathology:remarks on the necessity for maintaining the chest tumor registry[J].J Thorac Cardiovasc Surg,1939,9(1):119-131.
[2] Coffin CM,Watterson J,Priest JR,et al. Extrapulmonary inflammatory myofibroblastic tumor (inflammatory pseudotumor).A clinicopathologic and immunohistochemical study of 84 cases[J].Am J Surg Pathol,1995,19(8):859-872.
[3] Coffin CM,Patel A,Perkins S,et al. ALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor[J].Mod Pathol,2001,14(5):569-576.DOI:10.1038/modpathol.3880352.
[4] Coffin CM,Humphrey PA,Dehner LP.Extrapulmonary inflammatory myofibroblastic tumor:a clinical and pathological survey[J].Sem Diagn Pathol,1998,15(1):85-101.
[5] 陈兴明,高志强,姜鸿,等.原发于眶外的头颈部炎性肌纤维母细胞瘤14例临床分析[J].中华耳鼻咽喉头颈外科杂志,2013,48(4):307-310.DOI:10.3760/cma.j.issn.1673-0860.2013.04.010.
Chen XM,Gao ZQ,Jiang H,et al. Clinical analysis of 14 cases of primary head and neck inflammatory myofibroblastic tumor[J].Chin J Otorhinolaryngol Head Neck Surg,2013,48(4):307-310.DOI:10.3760/cma.j.issn.1673-0860.2013.04.010.
[6] Butrynski JE,D′Adamo DR,Hornick JL,et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor[J].N Engl J Med,2010,363(18):1727-1733.DOI:10.1056/NEJMoa1007056.
[7] Brooks JK,Nikitakis NG,Frankel BF,et al. Oral inflammatory myofibroblastic tumor demonstrating ALK,p53,MDM₂,CDK4,pRb,and Ki-67 immunoreactivity in an elderly patient[J].Oral Surg Oral Med Oral Pathol Oral Radiol Endod,2005,99(6):716-726.DOI:10.1016/j.tripleo.2004.11.023.
[8] Devaney KO,Lafeir DJ,Triantafyllou A,et al. Inflammatory myofibroblastic tumors of the head and neck:evaluation of clinicopathologic and prognostic features[J].Eur Arch Otorhinolaryngol,2012,269(12):2461-2465.DOI:10.1007/s00405-012-2026-3
[9] He CY,Dong GH,Yang DM,et al. Inflammatory myofibroblastic tumors of the nasal cavity and paranasal sinus:a clinicopathologic study of 25 cases and review of the literature[J].Eur Arch Otorhinolaryngol,2015,272(4):789-797.DOI:10.1007/s00405-014-3026-2.
[10] 刘艳丽,刘良发,黄德亮等.头颈部炎性肌纤维母细胞瘤临床分析[J].中华耳鼻咽喉头颈外科杂志,2014,49(1):35-38.DOI:10.3760/cma.j.issn.1673-0860.2014.01.009.
Liu Y,Liu L,Huang D,et al. Clinical features of inflammatory myofibroblastic tumor in the head and neck[J].Chin J Otorhinolaryngol Head Neck Surg,2014,49(1):35-38.DOI:10.3760/cma.j.issn.1673-0860.2014.01.009.
[11] Ong HS,Ji T,Zhang CP,et al. Head and neck inflammatory myofibroblastic tumor (IMT):evaluation of clinicopathologic and prognostic features[J].Oral Oncol,2012,48(2):141-148.DOI:10.1016/j.oraloncology.2011.09.004.
[12] D′Cunha A,Jehangir S,Thomas R.Inflammatory Myofibroblastic Tumor of Common Bile Duct in a Girl[J].APSP J Case Rep,2016,7:28.DOI:10.21699/ajcr.v7i4.445.
[13] Dishop MK,Warner BW,Dehner LP,et al. Successful treatment of inflammatory myofibroblastic tumor with malignant transformation by surgical resection and chemotherapy[J].J Pediatr Hematol Oncol,2003,25(2):153-158.